These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 25381142)

  • 21. [Epidemiology and natural history of nonalcoholic fatty liver disease].
    Pais R; Ratziu V
    Rev Prat; 2012 Dec; 62(10):1416-8, 1420-1. PubMed ID: 23424924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease.
    Demircioğlu F; Koçyiğit A; Arslan N; Cakmakçi H; Hizli S; Sedat AT
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):68-75. PubMed ID: 18607271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.
    Schindhelm RK; Heine RJ; Diamant M
    Diabetes Care; 2007 Sep; 30(9):e94; author reply e95. PubMed ID: 17726184
    [No Abstract]   [Full Text] [Related]  

  • 24. Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients.
    Mikolasevic I; Racki S; Zaputovic L; Lukenda V; Milic S; Orlic L
    Med Hypotheses; 2014 Feb; 82(2):205-8. PubMed ID: 24365277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease.
    Targher G
    Hepatology; 2005 Oct; 42(4):974-5; discussion 975. PubMed ID: 16175589
    [No Abstract]   [Full Text] [Related]  

  • 26. Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis.
    Barbarroja N; Pérez-Sanchez C; Ruiz-Limon P; Castro-Villegas C; Aguirre MA; Carretero R; Segui P; Jimenez-Gomez Y; Sanna M; Rodriguez-Ariza A; Collantes-Estevez E; Escudero A; López-Pedrera C
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2706-16. PubMed ID: 25256232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease.
    Villanova N; Moscatiello S; Ramilli S; Bugianesi E; Magalotti D; Vanni E; Zoli M; Marchesini G
    Hepatology; 2005 Aug; 42(2):473-80. PubMed ID: 15981216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease: a practical approach to evaluation and management.
    Rafiq N; Younossi ZM
    Clin Liver Dis; 2009 May; 13(2):249-66. PubMed ID: 19442917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of elevated serum alanine aminotransferase levels: think outside the liver.
    Ioannou GN
    Gastroenterology; 2008 Dec; 135(6):1851-4. PubMed ID: 19007778
    [No Abstract]   [Full Text] [Related]  

  • 31. Associations between liver histology and carotid intima-media thickness in patients with nonalcoholic fatty liver disease.
    Targher G; Bertolini L; Padovani R; Zoppini G; Zenari L; Falezza G
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2687-8. PubMed ID: 16306438
    [No Abstract]   [Full Text] [Related]  

  • 32. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease.
    Targher G; Day CP
    Hepatology; 2011 Jan; 53(1):375. PubMed ID: 20827721
    [No Abstract]   [Full Text] [Related]  

  • 33. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.
    Targher G; Arcaro G
    Atherosclerosis; 2007 Apr; 191(2):235-40. PubMed ID: 16970951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease: a challenge for pediatricians.
    Widhalm K; Ghods E
    Int J Obes (Lond); 2010 Oct; 34(10):1451-67. PubMed ID: 20838401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statins and nonalcoholic fatty liver disease: a bright future?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1089-93. PubMed ID: 23889731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease in India--how much? How soon?
    Duseja A; Chawla Y
    Trop Gastroenterol; 2005; 26(1):1-3. PubMed ID: 15974230
    [No Abstract]   [Full Text] [Related]  

  • 37. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease.
    Duseja A; Sharma B; Kumar A; Kapil S; Das A; Dhiman RK; Chawla YK
    Hepatology; 2010 Dec; 52(6):2248-9. PubMed ID: 20725907
    [No Abstract]   [Full Text] [Related]  

  • 38. Nonalcoholic fatty liver disease and cardiovascular disease risk.
    Brown TM
    Clin Gastroenterol Hepatol; 2012 Jun; 10(6):568-9. PubMed ID: 22387255
    [No Abstract]   [Full Text] [Related]  

  • 39. Insulin resistance links nonalcoholic fatty liver to cardiovascular diseases.
    Salamone F; Galvano F; Li Volti G
    Hepatology; 2011 May; 53(5):1785-6. PubMed ID: 21520192
    [No Abstract]   [Full Text] [Related]  

  • 40. [Relationship gene polymorphism adipor1 with cardiovascular risk in patients with nonalcoholic fatty liver disease].
    Kolesnikova O
    Georgian Med News; 2012 Dec; (213):40-4. PubMed ID: 23293232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.